161 related articles for article (PubMed ID: 34475433)
1. Influence of TGFB1 and CTLA4 polymorphisms on calcineurin inhibitors dose and risk of acute rejection in renal transplantation.
Bogacz A; Wolek M; Sieńko J; Czerny B; Machaliński B; Olbromski P; Kotowski M
Sci Rep; 2021 Sep; 11(1):17531. PubMed ID: 34475433
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.
Singh R; Srivastava A; Kapoor R; K Sharma R; D Mittal R
Naunyn Schmiedebergs Arch Pharmacol; 2009 Aug; 380(2):169-77. PubMed ID: 19343327
[TBL] [Abstract][Full Text] [Related]
3. IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.
Liu MZ; He HY; Zhang YL; Hu YF; He FZ; Luo JQ; Luo ZY; Chen XP; Liu ZQ; Zhou HH; Shao MJ; Ming YZ; Xin HW; Zhang W
Acta Pharmacol Sin; 2017 Mar; 38(3):415-423. PubMed ID: 28112181
[TBL] [Abstract][Full Text] [Related]
4. Molecular and structural consequences of early renal allograft injury.
Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
[TBL] [Abstract][Full Text] [Related]
5. Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients.
Seyhun Y; Ciftci HS; Kekik C; Karadeniz MS; Tefik T; Nane I; Turkmen A; Oguz FS; Aydin F
Int J Immunogenet; 2015 Jun; 42(3):147-60. PubMed ID: 25817300
[TBL] [Abstract][Full Text] [Related]
6. The influence of the tumor necrosis factor-alpa-308G>A polymorphism on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
M Kotowski M; Bogacz A; Bartkowiak-Wieczorek J; Sienko J; Procyk D; Dziewanowski K; Ostrowski M; Czerny B; Grzeskowiak E; Machalinski B
J Physiol Pharmacol; 2016 Dec; 67(6):819-826. PubMed ID: 28195062
[TBL] [Abstract][Full Text] [Related]
7. The effect of genetic variations for interleukin-10 (IL-10) on the efficacy of immunosuppressive therapy in patients after kidney transplantation.
Bogacz A; Polaszewska A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Sieńko M; Machaliński B; Sieńko J; Kotowski M
Int Immunopharmacol; 2020 Dec; 89(Pt A):107059. PubMed ID: 33039969
[TBL] [Abstract][Full Text] [Related]
8. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
9. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
[TBL] [Abstract][Full Text] [Related]
10. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.
Elens L; van Schaik RH; Panin N; de Meyer M; Wallemacq P; Lison D; Mourad M; Haufroid V
Pharmacogenomics; 2011 Oct; 12(10):1383-96. PubMed ID: 21902502
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
12. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
[TBL] [Abstract][Full Text] [Related]
13. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
Charpentier B; Rostaing L; Berthoux F; Lang P; Civati G; Touraine JL; Squifflet JP; Vialtel P; Abramowicz D; Mourad G; Wolf P; Cassuto E; Moulin B; Rifle G; Pruna A; Merville P; Mignon F; Legendre C; Le Pogamp P; Lebranchu Y; Toupance O; Hurault De Ligny B; Touchard G; Olmer M; Purgus R; Pouteil-Noble C; Glotz D; Bourbigot B; Leski M; Wauters JP; Kessler M
Transplantation; 2003 Mar; 75(6):844-51. PubMed ID: 12660513
[TBL] [Abstract][Full Text] [Related]
14. Association of cytotoxic T-lymphocyte antigen 4 +49A/G gene polymorphism with acute rejection risk in renal transplantation.
Yang CH; Chen XX; Chen L; Zheng DH; Liu QS; Xie WF
Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28333403
[TBL] [Abstract][Full Text] [Related]
15. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
16. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
17. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
18. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
Bolin P; Shihab FS; Mulloy L; Henning AK; Gao J; Bartucci M; Holman J; First MR;
Transplantation; 2008 Jul; 86(1):88-95. PubMed ID: 18622283
[TBL] [Abstract][Full Text] [Related]
19. A deeper understanding of the association between CTLA4 +49A/G and acute rejection in renal transplantation: an updated meta-analysis.
Gao JW; Zhou ZH; Guo SC; Guo YF; Guo F
Ren Fail; 2015 Feb; 37(1):165-74. PubMed ID: 25299395
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
